JP4733986B2 - HIVインテグラーゼ阻害薬として有用なテトラヒドロ−4H−ピリド[1,2−a]ピリミジン類および関連する化合物 - Google Patents

HIVインテグラーゼ阻害薬として有用なテトラヒドロ−4H−ピリド[1,2−a]ピリミジン類および関連する化合物 Download PDF

Info

Publication number
JP4733986B2
JP4733986B2 JP2004563339A JP2004563339A JP4733986B2 JP 4733986 B2 JP4733986 B2 JP 4733986B2 JP 2004563339 A JP2004563339 A JP 2004563339A JP 2004563339 A JP2004563339 A JP 2004563339A JP 4733986 B2 JP4733986 B2 JP 4733986B2
Authority
JP
Japan
Prior art keywords
oxo
hydroxy
fluorobenzyl
amino
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004563339A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006513200A (ja
JP2006513200A5 (cg-RX-API-DMAC7.html
Inventor
クレシエンツイ,ベネデツタ
キンツエル,オラフ
ムラグリア,エステル
オルビエート,フエデリカ
ペスカトーレ,ジヨバンナ
ローリー,マイケル
スンマ,ビンセンツオ
Original Assignee
イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー filed Critical イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー
Publication of JP2006513200A publication Critical patent/JP2006513200A/ja
Publication of JP2006513200A5 publication Critical patent/JP2006513200A5/ja
Application granted granted Critical
Publication of JP4733986B2 publication Critical patent/JP4733986B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2004563339A 2002-12-27 2003-12-18 HIVインテグラーゼ阻害薬として有用なテトラヒドロ−4H−ピリド[1,2−a]ピリミジン類および関連する化合物 Expired - Fee Related JP4733986B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43683002P 2002-12-27 2002-12-27
US60/436,830 2002-12-27
US52877603P 2003-12-12 2003-12-12
US60/528,776 2003-12-12
PCT/GB2003/005536 WO2004058756A1 (en) 2002-12-27 2003-12-18 Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors

Publications (3)

Publication Number Publication Date
JP2006513200A JP2006513200A (ja) 2006-04-20
JP2006513200A5 JP2006513200A5 (cg-RX-API-DMAC7.html) 2008-01-31
JP4733986B2 true JP4733986B2 (ja) 2011-07-27

Family

ID=32685467

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004563339A Expired - Fee Related JP4733986B2 (ja) 2002-12-27 2003-12-18 HIVインテグラーゼ阻害薬として有用なテトラヒドロ−4H−ピリド[1,2−a]ピリミジン類および関連する化合物

Country Status (20)

Country Link
US (2) US7414045B2 (cg-RX-API-DMAC7.html)
EP (1) EP1578748B1 (cg-RX-API-DMAC7.html)
JP (1) JP4733986B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050087865A (cg-RX-API-DMAC7.html)
CN (1) CN100343253C (cg-RX-API-DMAC7.html)
AT (1) ATE481401T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003292436B2 (cg-RX-API-DMAC7.html)
BR (1) BR0317749A (cg-RX-API-DMAC7.html)
CA (1) CA2509554C (cg-RX-API-DMAC7.html)
DE (1) DE60334248D1 (cg-RX-API-DMAC7.html)
EC (1) ECSP055890A (cg-RX-API-DMAC7.html)
HR (1) HRP20050593A2 (cg-RX-API-DMAC7.html)
IS (1) IS7892A (cg-RX-API-DMAC7.html)
MA (1) MA27583A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05007010A (cg-RX-API-DMAC7.html)
NO (1) NO20053624L (cg-RX-API-DMAC7.html)
NZ (1) NZ540729A (cg-RX-API-DMAC7.html)
PL (1) PL377354A1 (cg-RX-API-DMAC7.html)
RU (1) RU2329265C2 (cg-RX-API-DMAC7.html)
WO (2) WO2004058756A1 (cg-RX-API-DMAC7.html)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004062613A2 (en) * 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
CN1870896A (zh) * 2003-10-20 2006-11-29 默克公司 用作hiv整合酶抑制剂的羟基吡啶并吡咯并吡嗪二酮化合物
AR046938A1 (es) * 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) * 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7173022B2 (en) * 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) * 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) * 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
WO2006060225A2 (en) * 2004-11-23 2006-06-08 Merck & Co., Inc. Process for asymmetric synthesis of hexahydropyrimido[1,2-a] azepine-2-carboxamides and related compounds
BRPI0518741A2 (pt) * 2004-12-03 2008-12-02 Merck & Co Inc uso de uma combinaÇço de uma droga diretamente metabolizada por ugt1a1 ou um seu sal farmaceuticamente aceitÁvel e atazanavir ou um seu sal farmaceuticamente aceitÁvel, e, combinaÇço farmacÊutica para administraÇço oral a um mamÍfero
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
RU2382648C2 (ru) * 2004-12-03 2010-02-27 Мерк Энд Ко., Инк. Фармацевтический состав карбоксамидных ингибиторов интегразы вич, содержащий композицию с контролируемой скоростью высвобождения
EP3165220B2 (en) * 2004-12-03 2024-11-13 Merck Sharp & Dohme LLC Pharmaceutical composition containing an anti-nucleating agent
WO2006088173A1 (ja) * 2005-02-21 2006-08-24 Shionogi & Co., Ltd. Hivインテグラーゼ阻害活性を有する2環性カルバモイルピリドン誘導体
WO2006103399A1 (en) * 2005-03-31 2006-10-05 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
DK3187225T3 (da) * 2005-04-28 2022-02-28 Viiv Healthcare Co Polycyklisk carbamoylpyridonderivat med hiv-integrasehæmmende aktivitet
BRPI0613578A2 (pt) 2005-06-30 2012-01-17 Wyeth Corp composito da fórmula i; uso de um composto de fórmula i; e composição farmacêutica
US7494984B2 (en) * 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
JP5094725B2 (ja) * 2005-10-04 2012-12-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Hivインテグラーゼ阻害剤
AU2006306355A1 (en) * 2005-10-27 2007-05-03 Merck & Co., Inc. HIV integrase inhibitors
TW200800988A (en) 2005-10-27 2008-01-01 Shionogi & Amp Co Ltd Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
WO2007058646A1 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors: cyclic pyrimidinone compounds
WO2007059125A2 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7902182B2 (en) * 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) * 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007064316A1 (en) * 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
US20070129379A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Hiv integrase inhibitors
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
WO2007143446A1 (en) * 2006-05-30 2007-12-13 Bristol-Myers Squibb Company Spiro-condensed heterotricyclic compounds as hiv integrase inhibitors
US7893055B2 (en) * 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
US7763630B2 (en) * 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
US8129398B2 (en) * 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2349276B1 (en) * 2008-10-06 2019-11-27 Merck Sharp & Dohme Corp. Hiv integrase inhibitors
SG171308A1 (en) * 2008-12-11 2011-07-28 Shionogi & Co Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
PL2448940T3 (pl) * 2009-07-02 2014-10-31 Sanofi Sa Pochodne 6,7,8,9-tetrahydro-pirymido{1,2-a} pirymidyn-4-onu, ich wytwarzanie i zastosowanie farmaceutyczne
WO2011045330A1 (en) 2009-10-13 2011-04-21 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2010313571B2 (en) 2009-10-26 2014-07-31 Merck Sharp & Dohme Llc Solid pharmaceutical compositions containing an integrase inhibitor
WO2011121105A1 (en) 2010-04-02 2011-10-06 Tibotec Pharmaceuticals Macrocyclic integrase inhibitors
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
EP2931730B1 (en) 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
US9493479B2 (en) 2013-04-16 2016-11-15 Merck Sharp & Dohme Corp. Substituted pyrido[1,2-a]pyrazines as HIV integrase inhibitors
SI2997033T1 (en) 2013-05-17 2018-04-30 Merck Sharp & Dohme Corp. FUZYCLE TRICYCLE HETEROCYCLIC COMPOUNDS AS HIV INTEGRATED INHIBITORS
US9951079B2 (en) 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
CA2924829C (en) 2013-09-27 2019-10-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
EP3389380B1 (en) 2015-12-15 2021-07-21 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
WO2018102634A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
EP3805221A4 (en) 2018-05-31 2022-01-05 Shionogi & Co., Ltd POLYCYCLIC PYRIDONE DERIVATIVE
CR20230571A (es) 2018-05-31 2024-01-22 Shionogi & Co DERIVADO POLICÍCLICO DE CARBAMOILPIRIDONA (divisional 2020-0644)
WO2021107065A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 多環性ピリドピラジン誘導体

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306891B1 (en) * 1998-06-03 2001-10-23 Merck & Co., Inc. HIV integrase inhibitors
US6380249B1 (en) * 1998-06-03 2002-04-30 Merck & Co., Inc. HIV integrase inhibitors
US6262055B1 (en) * 1998-06-03 2001-07-17 Merck & Co., Inc. HIV integrase inhibitors
WO2001000578A1 (en) 1999-06-25 2001-01-04 Merck & Co., Inc. 1-(aromatic- or heteroaromatic-substituted)-3-(heteroaromatic substituted)-1,3-propanediones and uses thereof
DE60131160T2 (de) * 2000-06-07 2008-08-07 Vertex Pharmaceuticals Inc., Cambridge Caspase-inhibitoren und ihre verwendungen
GB0017676D0 (en) * 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2321348A1 (en) * 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
EP1326865B1 (en) * 2000-10-12 2009-05-06 Merck & Co., Inc. Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
JP2004517860A (ja) 2000-10-12 2004-06-17 メルク エンド カムパニー インコーポレーテッド Hivインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
AU1532802A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
AU2002230392A1 (en) 2000-10-12 2002-05-15 Merck & Co., Inc. AZA-and polyaza-naphthalenyl ketones useful as HIV integrase inhibitors
ATE530520T1 (de) 2001-08-10 2011-11-15 Shionogi & Co Antivirales mittel
DE122009000048I1 (de) * 2001-10-26 2010-04-08 Angeletti P Ist Richerche Bio N-substituierte hydroxypyrimidinoncarboxamid-hemmer der hiv-integrase
CA2463975A1 (en) * 2001-10-26 2003-05-01 Maria Emilia Di Francesco Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
EP1467970B1 (en) 2002-01-17 2007-08-22 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors
WO2004004657A2 (en) * 2002-07-09 2004-01-15 Bristol-Myers Squibb Company Hiv integrase inhibitors
WO2004062613A2 (en) * 2003-01-13 2004-07-29 Bristol-Myers Squibb Company Hiv integrase inhibitors
US7037908B2 (en) * 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
AR046938A1 (es) * 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares

Also Published As

Publication number Publication date
KR20050087865A (ko) 2005-08-31
JP2006513200A (ja) 2006-04-20
CN100343253C (zh) 2007-10-17
NZ540729A (en) 2008-03-28
NO20053624D0 (no) 2005-07-26
HRP20050593A2 (en) 2006-03-31
PL377354A1 (pl) 2006-01-23
NO20053624L (no) 2005-09-26
MXPA05007010A (es) 2005-08-18
US7968553B2 (en) 2011-06-28
CN1753892A (zh) 2006-03-29
EP1578748A1 (en) 2005-09-28
US20080176869A1 (en) 2008-07-24
US7414045B2 (en) 2008-08-19
BR0317749A (pt) 2005-11-22
AU2003292437A1 (en) 2004-07-22
DE60334248D1 (de) 2010-10-28
AU2003292436A1 (en) 2004-07-22
WO2004058756A1 (en) 2004-07-15
WO2004058757A1 (en) 2004-07-15
RU2329265C2 (ru) 2008-07-20
RU2005123807A (ru) 2006-01-20
CA2509554A1 (en) 2004-07-15
EP1578748B1 (en) 2010-09-15
ECSP055890A (es) 2005-09-20
IS7892A (is) 2005-06-13
AU2003292436B2 (en) 2009-07-30
MA27583A1 (fr) 2005-10-03
ATE481401T1 (de) 2010-10-15
US20060046985A1 (en) 2006-03-02
CA2509554C (en) 2011-02-01

Similar Documents

Publication Publication Date Title
JP2006513200A (ja) HIVインテグラーゼ阻害薬として有用なテトラヒドロ−4H−ピリド[1,2−a]ピリミジン類および関連する化合物
JP4523281B2 (ja) Hivインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
JP4252797B2 (ja) Hivインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
JP4287649B2 (ja) Hivインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
JP5116660B2 (ja) Hivインテグラーゼ阻害剤
JP4625838B2 (ja) Hivインテグラーゼ阻害薬
AU2007275816A1 (en) 1-hydroxy naphthyridine compounds as anti-HIV agents
JP2007528394A (ja) Hivインテグラーゼ阻害薬
JP2009507795A (ja) 化合物
US20120022045A1 (en) Bridged compounds as hiv integrase inhibitors
US20200069691A1 (en) Heterocyclic compounds as hiv protease inhibitors
BRPI0609437A2 (pt) compostos
AU2006299042B8 (en) HIV integrase inhibitors
UA74024C2 (en) A method for the treatment of states caused by ??38-kinases, and pyrrolotriazine compounds suitable for use as kinases inhibitors
ZA200504853B (en) Tetrahydro-4h-Pyrido[1,2-A]Pyrimidines and related compound useful as HIV integrase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100712

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110201

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20110121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110323

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110419

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110425

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140428

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees